bromodeoxyuridine has been researched along with sildenafil citrate in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chopp, M; Lu, M; Tsang, W; Wang, Y; Zhang, L; Zhang, R; Zhang, Z | 1 |
| Chen, J; Chopp, M; Wang, L; Zhang, L; Zhang, R; Zhang, Z; Zhu, Z | 1 |
| Chopp, M; Meng, H; Wang, Y; Zhang, C; Zhang, L; Zhang, RL; Zhang, ZG | 1 |
| Alvarez, FM; Bolz, M; Chopp, M; Cui, Y; Liu, Z; Lu, M; Szalad, A; Wang, L; Zhang, L; Zhang, RL; Zhang, ZG | 1 |
4 other study(ies) available for bromodeoxyuridine and sildenafil citrate
| Article | Year |
|---|---|
Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Behavior, Animal; Brain; Bromodeoxyuridine; Cell Count; Cell Division; Cerebrovascular Circulation; Corpus Striatum; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Dentate Gyrus; Disease Models, Animal; Lateral Ventricles; Male; Nerve Regeneration; Neurons; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Wistar; Recovery of Function; RNA, Messenger; Sildenafil Citrate; Stroke; Sulfones; Treatment Outcome | 2002 |
Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Brain; Bromodeoxyuridine; Cell Division; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Inhibitors; Guanylate Cyclase; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Donors; Nitroso Compounds; Piperazines; Purines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Sildenafil Citrate; Soluble Guanylyl Cyclase; Stroke; Sulfones; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2003 |
Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Aging; Animals; Bromodeoxyuridine; Cell Proliferation; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Endothelium, Vascular; Immunohistochemistry; Male; Neovascularization, Pathologic; Neuronal Plasticity; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Rats; Rats, Wistar; Sildenafil Citrate; Sodium Chloride; Stroke; Sulfones; Synapses; Synaptophysin; Time Factors; Treatment Outcome | 2005 |
Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain-Derived Neurotrophic Factor; Bromodeoxyuridine; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Complications; Diabetic Neuropathies; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Nerve Tissue Proteins; Neural Conduction; Pain Measurement; Pain Threshold; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Receptors, Leptin; RNA, Small Interfering; Schwann Cells; Sciatic Neuropathy; Sildenafil Citrate; Sulfones; Time Factors; Transfection | 2011 |